Menu Search
Equities

Aeterna Zentaris Inc

0UGB:LSE

Aeterna Zentaris Inc

Actions
  • Price (CAD)0.00
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of Dec 30 1899.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). The Company is engaged in the development of its therapeutic asset and has established a pre-clinical development pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS). Its therapeutic development pipeline includes AIM Biologicals, AEZS-150 and AEZS-130.

  • Revenue in CAD (TTM)3.23m
  • Net income in CAD-24.59m
  • Incorporated1990
  • Employees21.00
  • Location
    Aeterna Zentaris Inc315 Sigma DriveSUMMERVILLE 29486CanadaCAN
  • Phone+1 (418) 652-8525
  • Fax+1 (418) 948-9191
  • Websitehttps://www.zentaris.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		AEZS:TOR since
announced		Transaction
value
Ceapro IncAnnounced14 Dec 202314 Dec 2023Announced298.97%15.86m
Data delayed at least 15 minutes, as of May 17 2024.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.